Thymic Stromal Lymphopoietin Antikörper

Produktnummer ABIN2665442

Dieser Anti-Thymic Stromal Lymphopoietin-Antikörper ist ein Maus-Monoklonal-Antikörper zum Nachweis von Thymic Stromal Lymphopoietin in ELISA (Capture). Geeignet für Human.

Kurzübersicht für Thymic Stromal Lymphopoietin Antikörper (ABIN2665442)

Target: Thymic Stromal Lymphopoietin (TSLP)

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser Thymic Stromal Lymphopoietin Antikörper ist unkonjugiert

Applikation: ELISA (Capture)

Klon: 15B11-3

Produktdetails anti-Thymic Stromal Lymphopoietin Antikörper

Aufreinigung: The antibody was purified by affinity chromatography.

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu Thymic Stromal Lymphopoietin

Target: Thymic Stromal Lymphopoietin (TSLP)

Andere Bezeichnung: TSLP

Hintergrund: Thymic Stromal Lymphopoietin (TSLP) is a hemopoietic protein that is expressed in the heart, liver and prostate. TSLP overlaps biological activities with IL-7 and binds with the heterodimeric receptor complex consisting of the IL-7R alpha chain (IL-7Rα) and the TSLP-specific chain (TSLPR). Like IL-7, TSLP induces phosphorylation of STAT3 and STAT5, but uses kinases other than the JAKs for activation. TSLP prohibited apoptosis and stimulated growth of the human acute myeloid leukemia (AML)-derived cell line MUTZ3. It induces the release of T cell-attracting chemokines TARC and MDC from monocytes and activates CD11c(+) dendritic cells (DCs). TSLP activated DCs primed naive T cells to produce the proallergic cytokines (IL-4, IL-5, IL-13, TNFα) while down-regulating IL-10 and IFN-γ suggesting a role in initiating allergic inflammation. Recent studies revealed that expression of TSLP has a direct link to the pathogenesis of allergic inflammation such as atopic dermatitis and asthma via activating dendritic cells and mast cells which trigger inflammatory Th2 response characterized by high TNF-alpha and little IL-10 production.